877-744-1224

(file opens in new tab)

Caralluma Fimbriata Clinical Studies

Study #1

 

Effect of Caralluma Fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women

 

"Caralluma fimbriata is an edible cactus, used by tribal Indians to suppress hunger and enhance endurance. The effect of Caralluma extract was assessed in overweight individuals by a placebo controlled randomized trial. Fifty adult men and women (25–60 years) with a body mass index (BMI) greater than 25 kg/m2 were randomly assigned into a placebo or experimental group; the latter received 1 g of Caralluma extract per day for 60 days. All subjects were given standard advice regarding a weight reducing diet and physical activity. At the end of 30 and 60 days of intervention, blood glucose and lipids, anthropometric measurements, dietary intake and assessment of appetite was performed. Waist circumference and hunger levels over the observation period showed a significant decline in the experimental group when compared to the placebo group. While there was a trend towards a greater decrease in body weight, body mass index, hip circumference, body fat and energy intake between assessment time points in the experimental group, these were not significantly different between experimental and placebo groups. Caralluma extract appears to suppress appetite, and reduce waist circumference when compared to placebo over a 2 month period."

 

[Rebecca Kuriyan et al., Effect of Caralluma Fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women, Appetite 48 (2007) 338–344.]

 

Study #2

 

Caralluma fimbriata in the Treatment of Obesity

 

"This study consisted of 26 overweight patients, 19 on the active compound, Caralluma fimbriata, and 7 on placebo, who were followed for four weeks. Caralluma fimbriata has been used in Indian folklore medicine for centuries as an appetite suppressant that leads to long-term weight loss. The substance is well known in Ayurvedic medicine. It has shown a long safety record with little, if any, side effects. The substance showed a statistically significant reduction in bodyweight and was well tolerated."

 

[Ronald M. Lawrence and Suneeta Choudhary, Caralluma fimbriata in the Treatment of Obesity, in Proceedings of the 12th Annual World Congress of Anti-Aging Medicine, Las Vegas, Nev, USA, 2004.]

 

Study #3

 

Recent update in management of obesity and Overweight Patients: Standardized update of Caralluma fimbriata safe and effective therapy

 

"The complex process of appetite is controlled by several neural, humoral and psychological factors, and strategies that suppress appetite are likely to be useful in weight loss and control. Appetite suppressant medications, while effective, often have side effects. The Standardized Extract of Caralluma Fimbriata, an edible plant used for centuries in India as a famine food and appetite suppressant, is approved in India, Australia and the USA as a safe and effective option for management of obesity and overweight patients."

 

[Bansi Saboo MD et al., Recent update in management of obesity and Overweight Patients: Standardized update of Caralluma fimbriata safe and effective therapy, International Journal of Clinical Cases and Investigations 2011, Volume 2 (Issue1), 5:9.]

 

Study #4

 

Antiobesogenic and Antiatherosclerotic Properties of Caralluma fimbriata Extract

 

"The antiobesogenic effects of CFE were evaluated by monitoring changes in feed intake, body weight, serumlipid and hormonal (leptin) profiles, fat pads, and liver weight. Antiatherosclerotic effects were measured by histology. CFE induced significant and dose-dependent inhibition of food intake, with dose-related prevention of gains in body weight, liver weight, and fat pad mass. Alterations in serum lipid profiles associated with weight gain were similarly inhibited, as were the typical increases in serum leptin levels. These data substantiate CFE's reported anorexigenic effects. CFE treatment also conferred protection against atherogenesis. We conclude that CFE possesses antiobesogenic and antiatherosclerotic properties."

 

[Soundararajan Kamalakkannan et al., Antiobesogenic and Antiatherosclerotic Properties of Caralluma fimbriata Extract, Journal of Nutrition and Metabolism Volume 2010:1-6.]

 

Study #5

 

Caralluma fimbriata: A new dietary supplement in weight management strategies

 

"A double-blind, placebo-controlled, randomized clinical trial on Caralluma fimbriata extract was done on 50 human subjects. This study consisted of 50 obese patients, 25 on the active compound and 25 on placebo. The trial lasted for eight weeks. Caralluma fimbriata is an edible succulent cactus, that is native to India and well known amongst native Indian populations for its appetite suppressant properties- Subjects were tested for changes in key indicators of weight-loss, including anthropometry , body fat composition, BMI, net weight and systemic functions. The following are the key observations made in this trial: Statistically significant reductions were recorded in all key indicators of weight-loss 1 Caralluma fimbriata extract was well tolerated I Caralluma fimbriata extract showed minimal adverse effects which were gastrointestinal and transient in nature."

 

[Gencor Pacific, Caralluma fimbriata: A new dietary supplement in weight management strategies, at http://www.livestrong.com/article/189005-what-is-caralluma/, July 11, 2011.]

 
X
Password:
Wrong password.
']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); $(document).ready(function () { try { MotoJS.events.subscribe('onSwitchFinish', function() { try { _gaq.push(['_trackPageview', MotoJS.website.basePath + MotoJS.page.getUrl()]); }catch(e){} }); }catch(e){} });